文献速递神经肌肉病

杜氏肌营养不良症疾病轨迹建模

Modeling disease trajectory in Duchenne muscular dystrophy.
PubMed 文献 · Neurology · 2020-03-17

该研究纳入104例DMD患者和51例健康对照,每年随访至6年,用MRI和MRS测量腿部肌肉脂肪分数与定量T2,并以非线性混合效应累积分布函数建模。结果显示生物标志物随病程增加,股外侧肌半受累年龄比比目鱼肌早4.8年,皮质类固醇治疗平均延迟半受累年龄2.5年。

要点

  • MRS脂肪分数和MRI定量T2可敏感无创地量化DMD进展。
  • 股外侧肌半受累年龄比比目鱼肌早4.8年,与丧失行走年龄强相关。
  • 皮质类固醇治疗平均延迟半受累年龄2.5年,进展慢的肌肉延迟更明显。

核心结论

  • MRS脂肪分数和MRI定量T2是敏感的DMD进展无创指标,多肌肉建模可检测和监测皮质类固醇疗效并提供功能预后信息。

研究设计与样本

  • 前瞻性观察性研究,纳入104例DMD患者和51例健康对照,DMD患者每年随访至6年。

主要发现

  • MRS脂肪分数和MRI定量T2随DMD病程增加,进展时间常数在个体间和肌肉间差异显著。
  • 股外侧肌平均半受累年龄比比目鱼肌早4.8年,且与丧失行走年龄强相关。
  • 皮质类固醇治疗使各肌肉平均半受累年龄延迟2.5年,进展较慢的肌肉延迟更明显。

临床怎么用

  • 可利用MRS脂肪分数和MRI定量T2多肌肉建模来监测DMD进展和皮质类固醇治疗效果,并为功能预后提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To quantify disease progression in individuals with Duchenne muscular dystrophy (DMD) using magnetic resonance biomarkers of leg muscles. METHODS: MRI and magnetic resonance spectroscopy (MRS) biomarkers were acquired from 104 participants with DMD and 51 healthy controls using a prospective observational study design with patients with DMD followed up yearly for up to 6 years. Fat fractions (FFs) in vastus lateralis and soleus muscles were determined with 1H MRS. MRI quantitative T2 (qT2) values were measured for 3 muscles of the upper leg and 5 muscles of the lower leg. Longitudinal changes in biomarkers were modeled with a cumulative distribution function using a nonlinear mixed-effects approach. RESULTS: MRS FF and MRI qT2 increased with DMD disease duration, with the progression time constants differing markedly between individuals and across muscles. The average age at half-maximal muscle involvement (μ) occurred 4.8 years earlier in vastus lateralis than soleus, and these measures were strongly associated with loss-of-ambulation age. Corticosteroid treatment was found to delay μ by 2.5 years on average across muscles, although there were marked differences between muscles with more slowly progressing muscles showing larger delay. CONCLUSIONS: MRS FF and MRI qT2 provide sensitive noninvasive measures of DMD progression. Modeling changes in these biomarkers across multiple muscles can be used to detect and monitor the therapeutic effects of corticosteroids on disease progression and to provide prognostic information on functional outcomes. This modeling approach provides a method to transform these MRI biomarkers into well-understood metrics, allowing concise summaries of DMD disease progression at individual and population levels. CLINICALTRIALSGOV IDENTIFIER: NCT01484678.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Rooney WD, Berlow YA, Triplett WT, et al. Modeling disease trajectory in Duchenne muscular dystrophy. Neurology. 2020. PMID: 32184340. doi:10.1212/WNL.0000000000009244

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。